London, United Kingdom, September 30, 2019 --(PR.com)-- The conference will provide industry leaders with the unique opportunity to hear first-hand how the pharmaceutical industry is being shaped by developments in AI.

The latest early bird discount expires on September 30. Register early at www.disruptivetech-pharma.com/PRcom3 and save �400.

Attendees will learn valuable information from the experiences of key players in the market and gain greater understanding of the overall benefits AI provides for patients. Numerous sessions scheduled for the two-day conference focus on rapidly developing AI technologies.

Highlights include:

AI for Life
The potential of A.I. in health and the opportunities across the pharma pipeline

Concrete project examples from discovery through clinical trials and commercial, leveraging fundamental AI capabilities in cheminformatics, medical imaging, and NLP.

The challenges & foundation required for data scientists to make AI opportunities a reality

Nicholas Kelley, Data Science and AI Advisor, Novartis

AI-driven systems � focusing on practicalities of implementation

Discussing the impact of AI, ML and IoT on the pharmaceutical industry

Developing AI-enabled tools for improving patient access � where do we start?

Reflecting on global challenges of implementation and outlining strategies for improved incorporation

Exploring AI for identifying patients with rare disease and achieve early diagnosis � a case study

Peter Rutherford, Global Medical Lead, Vifor Pharma

Enabling AI Driven Drug Discovery with Cutting Edge "Disruptive" Platform

Gaining first-hand insight into AI-enabled drug discovery opportunities in pharma

Reviewing the disruptive technologies landscape through the eyes of an industry expert

Reflecting on strategies for AI-driven drug discovery

Bhushan Bonde, Head of IT - Early Solution Innovation Development, UCB

Two interactive post-conference half day workshops will take place on January 22nd.

Workshop A: "Disruptive Technologies: A Roadmap to Compliance with Technical, Evidence and Regulatory Standards" led by Mark Campbell, Freelance Regulatory Expert, former NICE | 8:30 � 12:00

Workshop B: "Build, Buy or Partner: Maximising Your Digital Health Impact" led by Karl Hess, Managing Director, OnDigitalHealth Consulting | 13:00 � 17:00

A speaker list and programme highlights are available for download from the event website at www.disruptivetech-pharma.com/PRcom3

Disruptive Technologies in Pharma
20�21 January 2020
London, UK
www.disruptivetech-pharma.com/PRcom3

Contact Information:
For media enquiries contact Alia Malick on +44 (0)20 7827 6168
For delegate enquiries contact Fateja Begum on +44 (0) 20 7827 6184

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world�s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk